Skip to main content
SpringerLink
Log in

99mTc-MIBI SPECT in small cell lung cancer patients before chemotherapy and after unresponsive chemotherapy

  • Original Articles
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We evaluated the accumulation of99mTc-MIBI in small cell lung cancer patients before chemotherapy and after unresponsive chemotherapy. The pre-chemotherapeutic group included 22 newly diagnosed patients. These patients underwent a99mTc-MIBI SPECT study before starting chemotherapy. After chemotherapy, based on changes in tumor size, three different patterns of response (complete remission: CR, partial remission: PR and no change: NC) were defined. The post-chemotherapeutic group included 11 patients after chemotherapy who did not respond to chemotherapy. These patients underwent a99mTc-MIBI SPECT study after completion of chemotherapy. SPECT images were acquired 15 min (early) and 2 hr (delayed) after injection of99mTc-MIBI. With a region of interest technique, the early ratio, delayed ratio and retention index were calculated. Early and delayed ratios in pre-chemotherapeutic patients were significantly higher than those in post-chemotherapeutic patients. There were no significant differences between the pre-chemotherapeutic and post-chemotherapeutic patients in the retention index. In the pre-chemotherapeutic patients, early and delayed ratios for the CR and PR groups were significantly higher than those for the NC group. There were no significant differences in the retention index with respect to the tumor response.99mTc-MIBI might be useful for evaluating the tumor chemosensitivity in patients with small cell lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nishiyama Y, Kawasaki Y, Yamamoto Y, Fukunaga K, Satoh K, Takashima H, et al.99mTc-MIBI and201Tl-chloride scintigraphy of primary lung cancer.J Nucl Med 1997; 38: 1358–1361.

    PubMed  CAS  Google Scholar 

  2. Hassan IM, Sahweil A, Constantinides C, Mahnud A, Nair M, Omar YT, et al. Uptake and kinetics of99mTc hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs.Clin Nucl Med 1989; 14: 333–340.

    Article  PubMed  CAS  Google Scholar 

  3. Kao CH, Wang SJ, Lin WY, Hsu CY, Liao SQ, Yeh SH. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile.Eur J Nucl Med 1993; 20: 249–254.

    PubMed  CAS  Google Scholar 

  4. Gottesman NM. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.Cancer Res 1993; 53: 747–754.

    PubMed  CAS  Google Scholar 

  5. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993; 53: 977–984.

    PubMed  CAS  Google Scholar 

  6. The Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer, November 1995, forth edn.

  7. Tonami N, Shuke N, Yokoyama K, Seki H, Takayama T, Kinuya S, et al. Thallium-201 single photon emission computed tomography in evaluation of suspected lung cancer.J Nucl Med 1989; 30: 997–1004.

    PubMed  CAS  Google Scholar 

  8. Kishida T. Mechanism of thallium-201 accumulation to thyroid gland: clinical usefulness of dynamic study in thallium-201 chloride scintigraphy for differential diagnosis of thyroid nodules.KAKU IGAKU (Jpn J Nucl Med) 1987; 24: 991–1004.

    CAS  Google Scholar 

  9. Ito Y, Muranaka A, Harada T, Matsudo A, Yokobayashi T, Terashima H. Experimental study on tumor affinity of201Tl-chloride.Eur J Nucl Med 1978; 3: 81–86.

    Article  PubMed  CAS  Google Scholar 

  10. Aktolun C, Bayhan H, Kir M. Clinical experience with99mTc-MIBI imaging in patients with malignant tumors: preliminary results and comparison with201Tl-chloride.Clin Nucl Med 1992; 17: 171–176.

    Article  PubMed  CAS  Google Scholar 

  11. Desai SP, Yuille DL. Visualization of a recurrent carcinoid tumor and an occult distant metastasis by technetium-99m-sestamibi.J Nucl Med 1993; 34: 1748–1751.

    PubMed  CAS  Google Scholar 

  12. Strouse PJ, Wang DC. Incidental detection of bronchogenic carcinoma during99mTc-SESTAMIBI cardiac imaging.Clin Nucl Med 1993; 18: 448–449.

    Article  PubMed  CAS  Google Scholar 

  13. Caner B, Kitapci M, Erbengi G, Gogus T, Bekdik C. Increased accumulation of99mTc-MIBI in undifferentiated mesenchymal tumor and its metastatic lung lesions.Clin Nucl Med 1992; 17: 144–145.

    Article  PubMed  CAS  Google Scholar 

  14. Yamamoto Y, Nishiyama Y, Satoh K, Takashima H, Ohkawa M, Fujita J, et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer.J Nucl Med 1998; 39: 1626–1629.

    PubMed  CAS  Google Scholar 

  15. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of Mitochondrial and plasma membrane potential on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts.J Nucl Med 1990; 31: 1646–1653.

    PubMed  CAS  Google Scholar 

  16. Schillaci O, Scoparino F, Scarpini M, Mingazzini PL, Danieli R, Banci M, et al. Is99mTc MIBI uptake in breast cancer related to neoangiogenesis? (abstract)Eur J Nucl Med 1994; 21: 747.

    Google Scholar 

  17. Ross EM. Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect. In: Goodman Gilmann A, Rall TW, Nies AS, Taylor P, eds.The Pharmacological Basis of Therapeutics. New York; McGraw-Hill, 1992: 33–49.

    Google Scholar 

  18. Ihde DC. Chemotherapy of lung cancer.N Engl J Med 1992; 12: 1434–1441.

    Google Scholar 

  19. Gottesman MM, Pastan I. The multidrug transporter, a double edged sword.J Biol Chem 1988; 263: 12163–12166.

    PubMed  CAS  Google Scholar 

  20. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance.Annu Rev Biochem 1989; 58: 134–171.

    Article  Google Scholar 

  21. Croop JM, Gros P, Housman DE. Genetics of multidrug resistance.J Clin Invest 1988; 81: 1303–1309.

    Article  PubMed  CAS  Google Scholar 

  22. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I.99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance:In vitro andin vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant.Nucl Med Commun 1995; 16: 253–257.

    Article  PubMed  CAS  Google Scholar 

  23. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, Van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.Eur J Nucl Med 1995; 22: 434–442.

    Article  PubMed  CAS  Google Scholar 

  24. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of99mTc-sestamibi.J Nucl Med 1994; 35: 510–515.

    PubMed  CAS  Google Scholar 

  25. Komori T, Matsui R, Adachi I, Shimizu T, Sueyoshi K, Narabayashi I.In vitro uptake and release of201Tl and99mTc-MIBI in Hela cell.KAKU IGAKU (Jpn J Nucl Med) 1995; 32: 651–658.

    CAS  Google Scholar 

  26. Ford JM, Hait MN. Pharmacology of drugs that alter multidrug resistance in cancer.Pharmacol Rev 1990; 42: 155–199.

    PubMed  CAS  Google Scholar 

  27. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.N Engl J Med 1991; 325: 1608–1614.

    PubMed  CAS  Google Scholar 

  28. Chin K-V, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene.Adv Cancer Res 1993; 60: 157–180.

    Article  PubMed  CAS  Google Scholar 

  29. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers.J Natl Cancer Inst 1989; 81: 116–124

    Article  PubMed  CAS  Google Scholar 

  30. Eijdems EW, De Haas M, Coco-Martin JM, Ottenheim CP, Zaman GJ, Dauwerse HG, et al. Mechanisms of MRP overexpression in four human lung-cancer cell lines and analysis of MRP amplicon.Int J Cancer 1995; 60: 676–684.

    Article  PubMed  CAS  Google Scholar 

  31. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment.Acta Oncologica 1992; 31: 205–213.

    Article  PubMed  CAS  Google Scholar 

  32. Bom HS, Kim YC, Song HC, Min JJ, Kim JY, Park KO.99mTc-MIBI uptake in small cell lung cancer.J Nucl Med 1998; 39: 91–94.

    PubMed  CAS  Google Scholar 

  33. Moretti JL, Caglar M, Boaziz C, Caillat-Vigneron N, Morere JF. Sequential functional imaging with99mTc hexakis-2-methoxyisobutylisonitrile and111In-octreotide: can we predict the response to chemotherapy in small cell lung cancer?Eur J Nucl Med 1995; 22: 177–180.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Kagawa Medical University, 1750-1 Ikenobe, Mikicho, Kita-gun, 761-0793, Kagawa, Japan

    Yuka Yamamoto, Yoshihiro Nishiyama, Kotaro Fukunaga, Katashi Satoh & Motoomi Ohkawa

  2. First Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan

    Jiro Fujita

Authors
  1. Yuka Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kotaro Fukunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katashi Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiro Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Motoomi Ohkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuka Yamamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, Y., Nishiyama, Y., Fukunaga, K. et al. 99mTc-MIBI SPECT in small cell lung cancer patients before chemotherapy and after unresponsive chemotherapy. Ann Nucl Med 15, 329–335 (2001). https://doi.org/10.1007/BF02988239

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02988239

Key words

Search

Navigation